|EVOTF -- USA Stock|| |
USD 20.25 0.60 3.05%
Dr. Mario Polywka was Chief Operating Officer and Member of the Management Board at Evotec AG since November 28, 2007. In 1991, he was a founding chemist of Oxford Asymmetry International plc, became Director of Chemistry in 1993 and a Board Director in 1996. In 1999, Dr. Polywka was appointed Chief Operating Officer and in 2001 Chief Executive Officer of OAI. Following the merger of EVOTEC BioSystems AG with OAI in 2000 he was Chief Operating Officer until 2002. Between 2002 and 2004, Dr. Polywka ran a number of spinout companies from Oxford and Southampton Universities. Dr. Polywka received his Bachelors degree from Hertford College, Oxford University and his Doctorate from the University of Oxford in mechanistic organometallic chemistry with Professor Steve Davies and continued at Oxford with postdoctoral studies on the biosynthesis of Penicillins with Professor Sir Jack Baldwin. He held a number of college teaching posts at Oxford University between 1988 and 1994
Age: 53 COO Since 2007 Ph.D
49 40 5 60 81 0 http://www.evotec.com
Polywka is a Fellow of the Royal Society of Chemistry and has a number of publications and patents mainly in the field of asymmetric synthesis. In May 2017, Dr. Mario Polywka became a member of the Board of Directors of Forge Therapeutics, Inc.